Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy SpringWorks Therapeutics stock | 68.88

Own SpringWorks Therapeutics stock in just a few minutes.

Posted

Fact checked

SpringWorks Therapeutics, Inc is a biotechnology business based in the US. SpringWorks Therapeutics shares (SWTX) are listed on the NASDAQ and all prices are listed in US Dollars. SpringWorks Therapeutics employs 71 staff and has a market cap (total outstanding shares value) of USD$3.2 billion.

How to buy shares in SpringWorks Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for SpringWorks Therapeutics. Find the stock by name or ticker symbol: SWTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until SpringWorks Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$68.88, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of SpringWorks Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of SpringWorks Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

SpringWorks Therapeutics share price

Use our graph to track the performance of SWTX stocks over time.

SpringWorks Therapeutics shares at a glance

Information last updated 2020-11-25.
Latest market close USD$68.88
52-week range USD$19.5 - USD$71.15
50-day moving average USD$59.8972
200-day moving average USD$46.5077
Wall St. target price USD$70
PE ratio 15.2917
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-44.684

Buy SpringWorks Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy SpringWorks Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

SpringWorks Therapeutics price performance over time

Historical closes compared with the close of $68.88 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-28) N/A
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

Is SpringWorks Therapeutics under- or over-valued?

Valuing SpringWorks Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of SpringWorks Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

SpringWorks Therapeutics's P/E ratio

SpringWorks Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, SpringWorks Therapeutics shares trade at around 15x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

SpringWorks Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -14.76%
Return on equity TTM -23.95%
Profit margin 0%
Book value $7.802
Market capitalisation USD$3.2 billion

TTM: trailing 12 months

Shorting SpringWorks Therapeutics shares

There are currently 3.0 million SpringWorks Therapeutics shares held short by investors – that's known as SpringWorks Therapeutics's "short interest". This figure is 6.4% up from 2.8 million last month.

There are a few different ways that this level of interest in shorting SpringWorks Therapeutics shares can be evaluated.

SpringWorks Therapeutics's "short interest ratio" (SIR)

SpringWorks Therapeutics's "short interest ratio" (SIR) is the quantity of SpringWorks Therapeutics shares currently shorted divided by the average quantity of SpringWorks Therapeutics shares traded daily (recently around 392127.05882353). SpringWorks Therapeutics's SIR currently stands at 7.65. In other words for every 100,000 SpringWorks Therapeutics shares traded daily on the market, roughly 7650 shares are currently held short.

However SpringWorks Therapeutics's short interest can also be evaluated against the total number of SpringWorks Therapeutics shares, or, against the total number of tradable SpringWorks Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SpringWorks Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 SpringWorks Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1981% of the tradable shares (for every 100,000 tradable SpringWorks Therapeutics shares, roughly 198 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against SpringWorks Therapeutics.

Find out more about how you can short SpringWorks Therapeutics stock.

SpringWorks Therapeutics share dividends

We're not expecting SpringWorks Therapeutics to pay a dividend over the next 12 months.

SpringWorks Therapeutics overview

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site